-
1.发明申请公开(公告)号：US20110190296A1
公开(公告)日：2011-08-04
申请号：US13084374
申请日：2011-04-11
申请人： Mohammad SALMAN , Jitendra SATTIGERI , Yatendra KUMAR , Ram Chander ARYAN , Vikram Krishna RAMANATHAN , Anita CHUGH
发明人： Mohammad SALMAN , Jitendra SATTIGERI , Yatendra KUMAR , Ram Chander ARYAN , Vikram Krishna RAMANATHAN , Anita CHUGH
IPC分类号： A61K31/5377 , C07D207/34 , A61K31/40 , A61P3/10 , A61P3/06 , A61P9/10 , A61P9/12 , A61P25/28 , C07D405/12 , A61K31/4025 , C07D413/06 , C07D401/06 , A61K31/454
CPC分类号： C07D207/34 , A61K31/40 , C07C69/716 , C07C69/738 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/14 , C07D413/04
摘要： The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
摘要翻译： 本发明涉及可用作3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂的取代吡咯衍生物。 本文公开的化合物可用作胆固醇降低剂，并且可用于治疗胆固醇相关疾病和相关症状。 提供了制备所公开化合物的方法，以及含有所公开化合物的药物组合物，以及治疗胆固醇相关疾病和相关症状的方法。
-
公开(公告)号：US20110190369A1
公开(公告)日：2011-08-04
申请号：US13084390
申请日：2011-04-11
申请人： Mohammad SALMAN , Jitendra SATTIGERI , Yatendra KUMAR , Ram Chander ARYAN , Vikram Krishna RAMANATHAN , Anita CHUGH
发明人： Mohammad SALMAN , Jitendra SATTIGERI , Yatendra KUMAR , Ram Chander ARYAN , Vikram Krishna RAMANATHAN , Anita CHUGH
IPC分类号： A61K31/40 , A61K31/4025 , A61P3/00
CPC分类号： C07D207/34 , A61K31/40 , C07C69/716 , C07C69/738 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/14 , C07D413/04
摘要： The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
-
公开(公告)号：US20110207933A1
公开(公告)日：2011-08-25
申请号：US13100833
申请日：2011-05-04
IPC分类号： C07D413/14
CPC分类号： C07D417/12
摘要： The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.
摘要翻译： 本发明涉及制备基本上纯的齐拉西酮的方法。 本发明还涉及齐拉西酮的酸加成盐的制备。 更具体地说，本发明涉及齐拉西酮基本上纯的盐酸盐的制备。 本发明还涉及药物组合物，其包括基本上纯的齐拉西酮或齐拉昔酮盐酸盐以及所述组合物用于治疗精神分裂症的用途。
-
公开(公告)号：US20090259047A1
公开(公告)日：2009-10-15
申请号：US12467051
申请日：2009-05-15
IPC分类号： C07D401/12
CPC分类号： C07D401/12 , A61K31/4439
摘要： The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
摘要翻译： 本发明涉及（S） - 奥美拉唑的结晶钡盐，其为（S）-5-甲氧基-2 - [[（4-甲氧基-3,5-二甲基-2-吡啶基） - 甲基]亚磺酰基〕-1H 苯并咪唑。 本发明还涉及制备（S） - 奥美拉唑的结晶钡盐的方法和包括如此制备的（S） - 奥美拉唑的结晶钡盐的药物组合物。
-
公开(公告)号：US20100145058A1
公开(公告)日：2010-06-10
申请号：US12703016
申请日：2010-02-09
IPC分类号： C07D401/12
CPC分类号： C07D401/12 , A61K31/4439
摘要： The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
摘要翻译： 本发明涉及（S） - 奥美拉唑的结晶钡盐，其为（S）-5-甲氧基-2 - [[（4-甲氧基-3,5-二甲基-2-吡啶基） - 甲基]亚磺酰基〕-1H 苯并咪唑。 本发明还涉及制备（S） - 奥美拉唑的结晶钡盐的方法和包括如此制备的（S） - 奥美拉唑的结晶钡盐的药物组合物。
-
6.发明申请公开(公告)号：US20090216029A1
公开(公告)日：2009-08-27
申请号：US12034838
申请日：2008-02-21
IPC分类号： C07D207/34
CPC分类号： C07D207/34
摘要： A process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided.
摘要翻译： 提供了制备无定形阿托伐他汀钙和稳定的无定形阿托伐他汀钙的方法。
-
公开(公告)号：US20110086884A1
公开(公告)日：2011-04-14
申请号：US12973499
申请日：2010-12-20
IPC分类号： A61K31/4439 , C07D401/12 , A61P1/04
CPC分类号： C07D401/12 , A61K31/4439
摘要： The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
摘要翻译： 本发明涉及（S） - 奥美拉唑的结晶钡盐，其为（S）-5-甲氧基-2 - [[（4-甲氧基-3,5-二甲基-2-吡啶基） - 甲基]亚磺酰基〕-1H 苯并咪唑。 本发明还涉及制备（S） - 奥美拉唑的结晶钡盐的方法和包括如此制备的（S） - 奥美拉唑的结晶钡盐的药物组合物。
-
公开(公告)号：US20100305328A1
公开(公告)日：2010-12-02
申请号：US12846479
申请日：2010-07-29
申请人： Prosenjit BOSE , Pramod KUMAR , Shilpi MITTAL , Yatendra KUMAR
发明人： Prosenjit BOSE , Pramod KUMAR , Shilpi MITTAL , Yatendra KUMAR
IPC分类号： C07D409/14
CPC分类号： C07D409/14
摘要： Processes for preparing pure tiagabine, a piperidine carboxylic acid, using pharmaceutically acceptable acid addition salts of tiagabine esters are provided. L(+)-tartaric acid, oxalic acid and dibenzoyl L(+)-tartaric acid addition salts of tiagabine esters are also provided. Further, processes for preparing acid addition salts of tiagabine esters are provided.
摘要翻译： 提供了使用噻加滨酯的药学上可接受的酸加成盐来制备纯噻加宾，哌啶羧酸的方法。 还提供了噻加滨酯的L（+） - 酒石酸，草酸和二苯甲酰L（+） - 酒石酸加成盐。 此外，提供了制备噻加滨酯的酸加成盐的方法。
-
公开(公告)号：US20100137607A1
公开(公告)日：2010-06-03
申请号：US12703004
申请日：2010-02-09
IPC分类号： C07D401/12
CPC分类号： C07D401/12 , A61K31/4439
摘要： The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.023 秒)
